Cerus Co. (NASDAQ:CERS – Get Free Report) insider Richard J. Benjamin sold 18,949 shares of Cerus stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $1.45, for a total value of $27,476.05. Following the completion of the sale, the insider now directly owns 715,850 shares in the company, valued at approximately $1,037,982.50. This represents a 2.58 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Cerus Price Performance
Shares of Cerus stock opened at $1.45 on Tuesday. The business’s 50 day simple moving average is $1.72 and its 200 day simple moving average is $1.75. Cerus Co. has a 52-week low of $1.38 and a 52-week high of $2.54. The firm has a market cap of $269.40 million, a PE ratio of -13.18 and a beta of 1.56. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59.
Cerus (NASDAQ:CERS – Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). The firm had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. On average, analysts predict that Cerus Co. will post -0.08 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 target price on shares of Cerus in a research report on Friday, February 21st.
View Our Latest Research Report on Cerus
Cerus Company Profile
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Stories
- Five stocks we like better than Cerus
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Can TikTok Stock Picks Really Make You Rich?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- The “Quality” Rotation: Back to Basics Investing
- Retail Stocks Investing, Explained
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.